120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
HIV 阳性患者使用 Biktarvy 并饮酒后高脂血症继发急性胰腺炎：一例病例报告
Authors Zheng R, Zhang Z , Yan J, Li F, Shi J
Received 14 November 2025
Accepted for publication 28 January 2026
Published 2 February 2026 Volume 2026:19 581484
DOI https://doi.org/10.2147/IMCRJ.S581484
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Thomas E Hutson
Rongrong Zheng, Zhongdong Zhang, Jun Yan, Feng Li, Jinchuan Shi
The Second Infectious Disease Department, Xixi Hospital of Hangzhou, Hangzhou, 310023, People’s Republic of China
Correspondence: Jinchuan Shi, The Second Infectious Disease Department, Xixi Hospital of Hangzhou, No. 2 Hengbu Street, Liuxia Town, Xihu District, Hangzhou, 310023, People’s Republic of China, Email shijinchuan2008@126.com
Abstract: The etiology of acute pancreatitis is multifactorial. Hypertriglyceridemia is the third most common cause of acute pancreatitis. Biktarvy, a recently approved human immunodeficiency virus (HIV) treatment, is a single tablet regimen in combination with bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF). A multitude of studies have identified a high risk of weight gain and hyperlipidemia, a trigger for acute pancreatitis, with Biktarvy use. This is the inaugural case of acquired immunodeficiency syndrome (AIDS) with acute pancreatitis as a secondary complication of Biktarvy and alcohol exposure, accompanied by cholelithiasis and diabetes. This case highlights the need for lipid monitoring in patients on Tenofovir Alafenamide (TAF)-based regimens.
Keywords: HIV, acute pancreatitis, hyperlipidemia, BIC/FTC/TAF
The Second Infectious Disease Department, Xixi Hospital of Hangzhou, Hangzhou, 310023, People’s Republic of China
Correspondence: Jinchuan Shi, The Second Infectious Disease Department, Xixi Hospital of Hangzhou, No. 2 Hengbu Street, Liuxia Town, Xihu District, Hangzhou, 310023, People’s Republic of China, Email shijinchuan2008@126.com
Abstract: The etiology of acute pancreatitis is multifactorial. Hypertriglyceridemia is the third most common cause of acute pancreatitis. Biktarvy, a recently approved human immunodeficiency virus (HIV) treatment, is a single tablet regimen in combination with bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF). A multitude of studies have identified a high risk of weight gain and hyperlipidemia, a trigger for acute pancreatitis, with Biktarvy use. This is the inaugural case of acquired immunodeficiency syndrome (AIDS) with acute pancreatitis as a secondary complication of Biktarvy and alcohol exposure, accompanied by cholelithiasis and diabetes. This case highlights the need for lipid monitoring in patients on Tenofovir Alafenamide (TAF)-based regimens.
Keywords: HIV, acute pancreatitis, hyperlipidemia, BIC/FTC/TAF